Signant Health Acquires VirTrial
Signant Health has announced the acquisition of VirTrial, a provider of software solutions for remote site startup and decentralized clinical trial conduct.
In addition to VirTrial's tele-research platform, which includes secure video, audio, chat, and connected medical device capabilities for decentralized patient-site interaction and assessments, the agreement provides Signant with a solution to address remote site startup and monitoring. Known as Virtual Site Monitoring, the solution leverages wearable technology for in-house or outsourced clinical research associates to remotely conduct site evaluation, initiation, and monitoring visits.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
